Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization

Chen Lin[1 #] , Rong Zhuona[1#] , Gu Yanlun[1,2] , Chen Yuke[3], Yu Wei[3] , Zhou Ying[1*] , Pang Xiaocong[1*]

[1] Department of Pharmacy, Peking University First Hospital, Xishiku Street, Xicheng District, 100034 Beijing, China

[1,2] School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191 Beijing, China

[3] Department of Urology Surgery, Peking University Third Hospital, Xueyuan Road 38, Haidian District, 100191 Beijing, China

*Corresponding author.

#Contributed equally.

Abstract

Background:

Due to the limitations in specificity of current diagnostic methods for prostate cancer (PCa), more reliable biomarkers are needed to explore for improving early detection. Plasma proteins represent a promising source of biomarkers, therefore understanding the causal relationships between specific plasma proteins and PCa could be conductive to identify novel biomarkers and therapeutic targets for PCa prevention and treatment.

Methods:

We performed a meta-analysis of two independent genome-wide association studies

(GWASs) including 94,397 individuals with PCa and 192,372 controls. A mendelian randomization (MR) supplemented by colocalization analysis was conducted, using *cis*-acting variants on 4,907 plasma proteins from deCODE Genetics (N=35,559) and 2,940 plasma proteins from UK Biobank Pharma Proteomics Project (UKB-PPP) (N=54,219). Then, the biological pathway analysis and druggability evaluation of the risk proteins were further performed.

Results:

Five possible susceptibility loci (JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3) for PCa were identified through the meta-analysis of GWASs. Among 3,722 plasma proteins, 193 proteins were associated with PCa risk, of which 20 high-risk proteins, including KLK3, were validated in both the deCODE and UKB-PPP cohorts. Functional annotation of these genes encoding proteins confirmed enrichment of immune response, inflammatory response, cell-cell interaction and so on. Genetic colocalization and druggable genome analyses also identified several potential drug targets for PCa, such as HSPB1, RRM2B and PSCA.

Conclusions:

We identified novel variants as well as several protein biomarkers linked to PCa risk and indicated pathways associated with PCa, which offered new insights into PCa etiology and contributed to development of novel biomarkers for early detection and potential therapeutic interventions.

Funding:

This work was supported by grants from Beijing Municipal Natural Science

Foundation (grant No. JQ24059, No. L234038) and National Natural Science Foundation of China (grant No. 82274015).

Keywords: Prostate cancer, Proteins, Biomarkers, Mendelian randomization, Colocalization analysis

Graphical abstract: A comprehensive study design summarized as follows.

Introduction

Prostate cancer (PCa) is the second most common malignancy with an estimation of 1.5 million new cases in 2022, which is account for 14% of total cancer diagnosed in men worldwide(Ferlay J, 2024). Even more worrying is that the number of new cases of PCa are projected to 2.9 million by 2040(James et al., 2024). Despite advancements in medical technology, early detection of PCa remains a significant challenge due to the limitations in specificity of current diagnostic methods, such as prostate-specific antigen (PSA) testing(Carter et al., 2013; Draisma et al., 2009; Oesterling, 1991). Therefore, there is an urgent need for more accurate and reliable biomarkers that can improve early detection and prognostic evaluations of PCa.

Plasma proteins have key roles in the development and progression of PCa, such as interleukin (IL)-6(Deichaite et al., 2022), insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-1(Cao et al., 2015). However, observational studies exploring the association between plasma proteins and PCa risk are often limited by confounding factors and selection bias, making it challenging to establish a clear causal relationship.

To overcome these limitations, Mendelian randomization (MR) offers a robust methodological approach. This approach utilizes the principle of random assortment of genes from parents to offspring, using genetic variation as an instrumental variable, which mimics the randomization process in a controlled trial, thereby minimizing the impact of reverse causality(Davies, Holmes, & Smith, 2018). With the recent development of proteomics technology, several large-scale proteomic studies have

identified over 18,000 protein quantitative trait loci (pQTLs) covering more than 4800 proteins(Ferkingstad et al., 2021; Pietzner et al., 2021). By using MR, researchers can gain a deeper comprehension of whether particular plasma proteins hold a causal nexus with PCa, thereby potentially unraveling novel biomarkers and targets for the prevention and treatment of PCa.

In this study, we performed a meta-analysis of two genome-wide association studies (GWAS) on PCa (PRACTICAL and FinnGen) for a total sample size of 94,397 cases and 192,372 controls. Based on GWAS summary statistics data from deCODE and UKB-PPP cohorts, we further performed a protein-wide MR (PW-MR) study, supplemented by colocalization analysis, to explore the casual relationship between plasma proteins and PCa risk. Moreover, we indicated biological processes and pathways associated with PCa, and evaluated the druggability of risk proteins. We aimed to identify novel plasma proteins biomarkers for PCa, which could address the limitations of current diagnostic methods and offer new insights into the biological mechanisms of PCa and potential therapeutic targets for intervention.

Results

Meta-analysis of the Genome-Wide Association Studies for Prostate Cancer

We conducted a meta-analysis combing two GWAS studies with a collective sample size of 94,397 individuals with PCa and 192,372 controls, aiming to identify genetic variants linked to PCa. The associations and assessment of SNPs heterogeneity that passed the genome-wide P-value threshold at these loci with PCa were presented in Supplementary Table 1. We found 5 genetic risk loci contained at least one SNP passing the genome-wide significance threshold of $P \leq 5\times10^{-8}$: JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3 (Figure 1). Among them, PDLIM5, WDPCP, EEFSEC and TNS3 were promising candidates as novel susceptibility loci associated with PCa. Supplementary Figure 1 displayed the associated quantile-quantile plot. The LocusZoom plots of the top SNPs at JAZF1, PDILM5, WDPCP, EEFSEC and TNS3, along with their genomic location, GWAS P values and recombination rate with neighboring SNPs were visualized in Supplementary Figure 2. In summary, this GWAS meta-analysis discovered genetic variations in one recognized PC-associated loci and four potential novel loci, providing a reliable dataset for MR analyses.

Cross-phenotype Analysis of Prostate Cancer

We used the iCPAGdb to conduct the cross-phenotype genetic association analyses with PCa genome-wide significant SNPs ($P \leq 5\times10^{-8}$). The iCPAGdb offered an improved algorithm for identifying cross-phenotype associations by using pre-computed ancestry-specific LD databases and integrating genetic data from 3793 traits in the NHGRI-EBI GWAS catalog(L. Wang et al., 2020). After adjusting for

109 Bonferroni's correction, the cross-phenotype analysis indicated that 117 traits showed
110 significant association with PCa (Supplementary Table 2). As shown in Figure 2, the
111 top 10 enrichments were for prostate specific antigen measurement ($P=7.16\times10^{-43}$),
112 body height ($P=2.18\times10^{-30}$), BMI-adjusted waist-hip ratio ($P=1.32\times10^{-26}$), high
113 density lipoprotein cholesterol measurement ($P=2.38\times10^{-22}$), systolic blood pressure
114 ($P=2.93\times10^{-22}$), balding measurement ($P=3.01\times10^{-22}$), leukocyte count ($P=3.46\times10^{-}$
115 ^{21}), blood protein measurement ($P=4.95\times10^{-21}$), body mass index ($P=1.71\times10^{-20}$) and
116 heel bone mineral density ($P=2.02\times10^{-19}$).

117 **Proteome-Wide Mendelian Randomization Studies of Prostate Cancer**

118 The genetic association summary statistics of 35,559 Icelanders from deCODE
119 Genetics and 54,219 Europeans from the UKB-PPP were utilized to investigate the
120 relationship between PCa and plasma proteins. Our genetic instrument selection
121 strategy enabled us to examine 1778 and 1944 proteins from deCODE and UKB-PPP
122 (Supplementary Table 3A and B). Using the Wald ratio or IVW method, a total of 193
123 unique plasma proteins were significantly associated with PCa after multiple tests
124 with a 5% FDR correction. This analysis yielded 137 proteins in UKB-PPP more than
125 76 proteins in deCODE (Figure 3A). The results of Heterogeneity test based on Q
126 statistics showed little evidence of heterogeneity. Furthermore, no significant
127 intercept was detected, implying that there was no directional pleiotropy observed.

128 After FDR correction, 20 proteins were detected in both data sets and the identified
129 associations were consistent (Figure 3B). Genetic prediction indicated that 11 of these
130 20 proteins were positively associated with the risk of PCa as well as remaining 9

131 proteins were negatively associated, suggesting that these 9 proteins maybe protective
132 factors against PCa (Supplementary Table 4). A PhenoGram depicted the
133 chromosomal location of the 193 unique identified proteins in deCODE and UKB-
134 PPP studies (Figure 3C).

135 **Colocalization analysis**

136 We performed colocalization analyses of proteins significantly expressed in deCODE
137 and UKB-PPP studies with PCa. It was observed that 4 proteins in deCODE study and
138 7 proteins in UKB-PPP were colocalized with PCa associations with high support of
139 evidence (PPH4 $\geq$ 0.8) (Table 1), suggesting that these 10 plasma proteins might serve
140 as potential targets for treating PCa. Among them, SERPINA3 showed strong
141 colocalization evidence in both decode (PPH4=0.952) and UKB-PPP (PPH4=0.951)
142 studies. This analysis identified 1 causal variant in deCODE (rs61976125) and 1
143 causal variant in Fenland (rs6575449) (Figure 4).

Table 1. Analysis of Mendelian randomization and colocalization of significant proteins with PCa.

GWAS	Outcomes	Proteins	Mendelian randomization			Colocalization
			OR (95%CI)	P value	P value after FDR adjustment	Analysis PH4
deCODE	Prostate Cancer	MSMB	0.86(0.84,0.88)	1.56E-27	2.82E-24	0.999
		POGLUT3	0.89(0.83,0.96)	1.16E-03	2.44E-02	0.998
		PRSS3	0.93(0.91,0.94)	1.00E-18	6.03E-16	0.956
		SERPINA3	1.11(1.06,1.15)	7.18E-08	1.05E-05	0.952
UKB-PPP	Prostate Cancer	USP28	0.47(0.40,0.56)	7.27E-17	2.89E-14	0.999
		KLK3	9.70(4.94,19.03)	3.83E-11	6.91E-09	0.999
		IGFBP3	1.07(1.05,1.09)	2.04E-11	4.49E-09	0.997
		CASP10	1.22(1.11,1.34)	4.73E-05	1.54E-03	0.988
		HDGF	0.96(0.95,0.97)	2.61E-17	1.29E-14	0.966
		SERPINA3	1.10(1.07,1.13)	1.64E-10	2.32E-08	0.951
		C5	1.19(1.11,1.27)	5.32E-07	4.06E-05	0.883

OR, odds ratio; CI, confidence interval; FDR, false discovery rate.

146 **Gene-Based Association and Pathway Analyses**

147 We used the GENE2FUNC tool available in FUMA to explore the biological
148 significance, functional implications and tissue-specific expression of the genes
149 identified from our GWAS. These genes appeared to be significantly enriched in
150 inflammatory and immune pathways (such as defense, immune and inflammatory
151 response), as well as cell interaction and signaling pathways (such as interaction
152 between organism and cell adhesion) (Figure 5A). The KEGG pathway enrichment
153 analysis revealed several pathways that were significantly enriched, such as cytokine-
154 cytokine receptor interaction, p53 signaling pathway, JAK-STAT signaling pathway,
155 pathways in cancer and apoptosis (Figure 5B). These analyses indicated potential
156 biological processes and mechanisms associated with PCa. The 193 unique genes
157 were predominantly expressed in the lymphocytes, blood, liver and prostate
158 (Supplementary Figure 3).

159 **Druggability of identified proteins**

160 Exploring new therapeutic opportunities for PCa based on genetic information is
161 crucial for developing targeted treatments. In our study, we examined the druggability
162 of genes and proteins identified in MR analyses using OpenTargets databases. We
163 investigated 128 unique drugs targeting 45 identified proteins (Supplementary Table
164 5). Among these, three drugs (APATORSEN, TRIAPINE and MK-4721) currently in
165 clinical trials were intended for PCa treatment, with each targeting HSPB1, RRM2B
166 and PSCA, respectively. Notably, the effects of these drugs on their respective protein
167 targets align with the directions indicated by our MR results, suggesting a consistency

between genetic evidence and therapeutic potential. In addition, several other identified targets, such as RET, FGFR3, NCAM1, TYMP, TNFRSF10B, MMP3, TACSTD2 and NOTCH2, were implicated in various cancers and present potential therapeutic avenues.

Discussion

In this study, we conducted a comprehensive meta-analysis of two GWAS for PCa, identifying significant genetic loci associated with PCa risk. The combined sample size of 94,397 cases and 192,372 controls revealed one known (JAZF1) and four potential novel (PDLIM5, WDPCP, EEFSEC and TNS3) susceptibility loci of PCa. JAZF1 (Juxtaposed with another zinc finger gene 1) is a transcriptional repressor of testicular nuclear receptor 4 (TR4) (Nakajima, Fujino, Nakanishi, Kim, & Jetten, 2004). Several GWAS studies have implicated that JAZF1 is highly associated with type 2 diabetes and PCa risk(Frayling, Colhoun, & Florez, 2008; Machiela et al., 2012; Saxena, Voight, Zeggini, Scott, & Genetics, 2008; Thomas et al., 2008). JAZF1 may influence the risk of PCa through its role in metabolic regulation(Rosario et al., 2023) and cellular proliferation(Sung et al., 2018).

PDLIM5 (PDZ and LIM domain 5) is a member of the enigma subfamily and features a N-terminal PDZ domain and three C-terminal LIM domains(X. J. Wang & Su, 2010). A study implicated that downregulating the expression of PDLIM5 could ultimately impede the progression of PCa(Xie et al., 2020). WDPCP, a PCP effector, can regulate PCP by directly modulating the actin cytoskeleton(Cui et al., 2013). Disruption of PCP signaling can cause abnormal cell behavior and tissue structure, leading to the development of cancer(Humphries & Mlodzik, 2018). EEFSEC (eukaryotic elongation factor, selenocysteine-tRNA specific) was identified as a genome-wide significant loci in recent chronic obstructive pulmonary disease GWAS(Hobbs et al., 2017; Wain et al., 2017). TNS3 (Tensin 3) is involved in cell

194 migration, invasion and adhesion processes(Chen et al., 2017; Martuszewska et al.,
195 2009; Zheng et al., 2021; Zuidema et al., 2022), which are critical in cancer
196 metastasis. To certain whether these 4 genes causative factors for PCa, genetic
197 association studies with a larger sample size will be needed.

198 In the cross-phenotype Analysis of PCa, we found that prostate specific antigen (PSA)
199 measurement, BMI-adjusted waist-hip ratio (WHR), high density lipoprotein
200 cholesterol (HDL) measurement, systolic blood pressure, balding measurement and
201 other traits were significantly associated with PCa. These findings highlighted the
202 multifactorial nature of PCa and underscored the importance of considering a broad
203 range of physiological and biochemical factors in understanding its etiology and
204 progression.

205 PSA measurement, a protein secreted by both normal and malignant prostate epithelial
206 cells, has long been a cornerstone in the early detection and monitoring of
207 PCa(Oesterling, 1991). However, the specificity and sensitivity of PSA as a diagnostic
208 tool have been questioned due to its elevation in benign conditions such as prostatitis
209 and benign prostatic hyperplasia, leading to unnecessary biopsies(Carter et al., 2013)
210 and substantial overdiagnosis(Draisma et al., 2009). Therefore, supplementary
211 biomarkers are urgently needed to improve diagnostic accuracy.

212 Obesity has emerged as a significant risk factor in cancer development(Petrelli et al.,
213 2021), such as aggressive PCa(Moyad, 2015). The significant association between
214 BMI-adjusted WHR and PCa suggested that central obesity may play a critical role in
215 the development of PCa(Perez-Cornago, Dunneram, Watts, Key, & Travis, 2022).

Central adiposity, primarily referring to visceral adipose tissue, can influence hormone levels and inflammatory processes, thereby contributing to carcinogenesis(Doyle, Donohoe, Lysaght, & Reynolds, 2012). HDL cholesterol is known for its atherosclerotic protective effects(Rohatgi, Westerterp, von Eckardstein, Remaley, & Rye, 2021), mainly due to the ability to promote the reverse transport of cholesterol from peripheral cells to the liver for excretion(Cuchel & Rader, 2006), and to exert antioxidant and anti-inflammatory activities. Through similar mechanisms, HDL may influence the development and progression of tumors, by directly interacting with cancer cells or by modifying the tumor microenvironment(Ossoli, Wolska, Remaley, & Gomaraschi, 2022). Higher HDL levels might confer a protective effect against PCa by influencing cancer cells proliferation, possibly through mechanisms involving antioxidant(Ruscica et al., 2018) and anti-inflammatory properties.

Results from previous studies of the association between hypertension and PCa development have been inconsistent(Christakoudi et al., 2020; Liang et al., 2016; Seretis et al., 2019). One MR analysis suggested that elevated systolic blood pressure might be linked to an increased risk of PCa, potentially due to systemic inflammation(Stikbakke et al., 2022), which contributed to a pro-tumorigenic environment by promoting cellular proliferation, DNA damage, and resistance to apoptosis(Mantovani, Allavena, Sica, & Balkwill, 2008). However, the precise relationship between systolic blood pressure and PCa remains unclear. More research is needed to elucidate the exact biological pathways involved and to determine

238 whether managing hypertension could serve as a preventive strategy for PCa.

239 The underlying mechanism for the link between androgenic alopecia and an increased
240 risk of PCa may involve androgen metabolism, as both conditions are influenced by
241 dihydrotestosterone (DHT) levels. Elevated DHT can promote the miniaturization of
242 hair follicle leading to balding(Kaufman, 1996), as well as stimulate prostate cell
243 proliferation(Tong et al., 2022), contributing to the development of PCa. While these
244 associations highlight a potential shared hormonal pathway, further studies are needed
245 to confirm the causality. Overall, our cross-phenotype analysis provided a
246 comprehensive view of the diverse factors associated with PCa and enhanced our
247 understanding of the disease's multifaceted nature. Future researches should focus on
248 elucidating the underlying mechanisms of these associations and exploring their
249 potential for integration into clinical practice.

250 We performed a PW-MR study supplemented by colocalization analysis to explore the
251 casual association of 3,722 plasma proteins with the risk of PCa. MR analysis
252 identified a total of 193 unique proteins significantly associated with PCa, of which
253 10 proteins had a strong support of colocalization. Microseminoprotein-beta
254 (MSMB), also known as PSP94 or beta-inhibin, as an immunoglobulin superfamily
255 protein and one of the most abundant proteins secreted by prostate epithelial cells has
256 the strongest correlation(Byrne et al., 2019). We predicted that men with lower blood
257 levels of MSMB have higher risk of PCa, based on two European ancestry cancer
258 GWAS studies. These results were consistent with another published prospective
259 study(Haiman et al., 2013), supporting a potential protective role of MSMB in the

260 development of PCa. One previous publication reported that the decreased expression
261 of MSMB was both in the tumor (especially in more advanced tumor) and adjacent
262 benign prostate tissue(Bergström, Järemo, Nilsson, Adamo, & Bergh, 2018), which is
263 not in conflict as it may be related to aggressiveness of prostate tumors. Although the
264 mechanism of action of MSMB in PCa is unclear, it has been shown to control
265 prostate cell growth by regulating apoptosis(Garde et al., 1999). In addition to our
266 study, several other studies also supported the potential of MSMB as a serum marker
267 for the early detection of PCa(Nam et al., 2006; Reeves, Dulude, Panchal, Daigneault,
268 & Ramnani, 2006). Consequently, further research is essential to explore the
269 functional role and possible clinical utility of MSMB in PCa.
270 Serine protease inhibitor A3 (SERPINA3), an inhibitors of serine proteases that
271 promotes tumor development by regulating the transcription of some oncogenes and
272 its elevation was associated with a worse prognosis in some cancers(De Mezer et al.,
273 2023). SERPINA3 was up-regulated in PCa cells and enhanced cells migration and
274 invasion(Z. S. Xing, Li, Liu, Zhang, & Bai, 2021), which was consistent with our
275 prediction of it as a risk factor in this MR Study. A study identified that the enhanced
276 expression of SERPINA3 stimulated the bone environment, therefore it may be served
277 as a diagnostic biomarker to predict PCa with bone metastasis phenotype and
278 survival(Ito et al., 2023).
279 Protease serine 3 (PRSS3), also named mesotrypsin, is reported to be aberrantly
280 expressed in various types of tumors and participates in the progression and
281 development of cancers. For example, PRSS3 was identified to be downregulated in

282 lung cancer(Zhou, Li, & Luo, 2023) but upregulated in pancreatic cancer(Jiang et al.,
283 2010; C. J. Xing et al., 2019), suggesting it may have different roles depending on the
284 cellular or disease ways. A study of *vivo* and *vitro* experiments has demonstrated that
285 PRSS3 played an important role in PCa metastasis(Hockla et al., 2012). Despite these
286 findings, further studies are necessary to fully understand the functions and
287 mechanisms of PRSS3 in human PCa.
288 KLK3 (Kallikrein Related Peptidase 3), also known as PSA, is a serine protease
289 predominantly expressed in the prostate gland. One potential mechanism through
290 which KLK3 may influence PCa development involved its proteolytic activity, which
291 can degrade extracellular matrix components and facilitate tumor invasion and
292 metastasis(Avgeris, Mavridis, & Scorilas, 2012; Lawrence, Lai, & Clements, 2010;
293 Mavridis, Avgeris, & Scorilas, 2014). Additionally, the androgen regulation of KLK3
294 expression correlated with the androgen receptor signaling pathway, a critical driver
295 of PCa progression, particularly in castration-resistant prostate cancer (CRPC)(Lilja,
296 Ulmert, & Vickers, 2008). Despite these insights, the precise biological pathways
297 through which KLK3 contributes to PCa progression remain incompletely understood.
298 Further research is needed to illustrate the direct and indirect effects of KLK3 on PCa
299 cells and the tumor microenvironment.
300 Lastly, the druggability evaluation identified 45 protein biomarkers that have been
301 targeted by 128 drugs. Among these, three drugs targeting HSPB1, RRM2B and
302 PSCA, respectively, are currently in clinical trials for potential use in PCa treatment.
303 HSPB1, also known as human HSP27, is a small heat-shock protein that functions as

304 a molecular chaperone, protecting cells against stress-induced damage and
305 apoptosis(Okuno, Adachi, Kozawa, Shimizu, & Yasuda, 2016). It was overexpressed
306 in various cancers(Sheng et al., 2017; Shi et al., 2019), including PCa(Shiota et al.,
307 2013; Vasiljevic et al., 2013), and was associated with tumor progression, metastasis
308 and resistance to therapy. Evidences in *vitro* and in *vivo* suggested that inhibiting
309 HSP27 inhibits tumor growth and sensitivity to cytotoxic chemotherapy(Hadaschik et
310 al., 2008; Kamada et al., 2007). APATORSEN is an antisense oligonucleotide
311 designed to inhibit HSPB1 expression(Jansen & Zangemeister-Wittke, 2002), which
312 is still in clinical trials.
313 RRM2B is a subunit of ribonucleotide reductase, an enzyme critical for DNA
314 synthesis and repair(Okumura et al., 2005). Its expression was upregulated in
315 response to DNA damage and was involved in maintaining genomic stability(Aye, Li,
316 Long, & Weiss, 2015; Foskolou et al., 2017). Elevated levels and distinct mutation
317 signatures of RRM2B have been linked to poor prognosis in several cancers(Iqbal et
318 al., 2021). PSCA is a cell surface glycoprotein highly expressed in high-grade PCa(Gu
319 et al., 2000; Zhigang & Wenlv, 2004) and other solid tumors(Teng et al., 2022), and
320 was involved in cell proliferation, adhesion and survival(Li et al., 2017).
321 This study possessed several strengths, including the use of the largest collection of
322 plasma protein data (coving more than 4800 proteins), large sample sizes of GWAS
323 studies, a mutual validation across two independent outcome datasets and the use of
324 colocalization analysis to support the MR results. Additionally, our assessment of the
325 human blood proteome relied on two technologies (SOMAmer and Olink), which

326 were valuable for identifying plasma proteins associated with diseases traits such as
327 PCa.
328 Some limitations of our analysis should be acknowledged. Firstly, this investigation
329 was only confined to Europeans, restricting the applicability of our findings to other
330 populations. It is crucial for future studies to identify risk proteins in more diverse
331 populations, especially African ancestry who face a higher risk of PCa. Moreover, our
332 study concentrated on the proteins available in the MR analysis, which likely led to
333 the omission of other potential therapeutic targets. Lastly, we utilized proteomic data
334 from Icelanders whose genetic backgrounds may differ from other European
335 populations, which might introduce bias. However, this potential bias might be
336 minimal, as we found that 20 proteins showing significance ($P<0.05$) in both the
337 deCODE and UKB-PPP studies had consistent associations with PCa.
338 In conclusion, we conducted a large-scale PW-MR study using the MR and
339 colocalization analysis to investigate the genetic associations of up to 3,722 unique
340 proteins with PCa. We revealed the complex genetic architecture of PCa and
341 identified many new plasma proteins with strong causal associations to PCa. These
342 findings highlighted the potential biomarkers for early detection and therapeutic
343 targets, providing a foundation for future research and potential clinical applications.

Methods

Data sources for plasma proteins

We selected *cis*-SNPs associated with plasma proteins as instrumental variables from two large-scale GWASs in the deCODE Genetics(Ferkingstad et al., 2021) and UKB-PPP(Sun et al., 2023). Cis-SNPs were defined as SNPs within a vicinity of ±1 Mb around the gene encoding the protein. From these SNPs, only those with a minor allele frequency of ≥ 1% that were genome-wide significance ($p < 5\times10^{-8}$) and considered independent (linkage disequilibrium $r^2 < 0.1$ in 1000G) were retained. deCODE Genetics conducted proteomic profiling on blood plasma samples from 35,559 Icelanders using the SomaScan platform and collected data on 4907 aptamers(Ferkingstad et al., 2021). For the two-sample MR analysis, we selected cis-SNPs as instrumental variables for 1778 proteins. Likewise, cis-SNPs for 1944 plasma proteins were obtained from the UKB-PPP where 2940 proteins were measured among 54,219 Europeans using the Olink platform(Sun et al., 2023). The proteins with positive MR results were included in the colocalization analysis.

Data sources for Prostate Cancer

GWAS summary statistics for PCa were obtained from the PRACTICAL consortium(Schumacher et al., 2018) and FinnGen study. The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) consortium included 79,198 cases and 61,106 controls. We used the data on PCa from the FinnGen study R10 in this analysis, which comprised 15,199 cases and 131,266 controls. All participants of these two cohorts were of European ancestry. In

366 the MR analysis, we treated the PRACTICAL consortium as the discovery study and
367 the FinnGen R10 study as the replication. To increase the effectiveness, we performed
368 a fixed-effect GWAS meta-analysis of the two GWASs using the METAL package.
369 The quantile-quantile plot was generated using the "qqman" package in R software.
370 The R package "gassocplot" was used to plot regional association plots for the top
371 SNP at each of the genome-wide significant loci identified.

372 **Cross-phenotype analysis**

373 Through the interactive Cross-Phenotype Analysis of GWAS database (iCPAGdb)(L.
374 Wang et al., 2020), a new platform for cross-phenotype analysis, we explored the
375 genetic correlation between PCa and other traits. We analyzed the genetic correlations
376 between PCa and 3793 traits using data from the National Human Genome Research
377 Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS catalog(L. Wang et
378 al., 2020). Through the use of ancestry LD-specific association data, iCPAGdb
379 performs cross-phenotype enrichment analyses. iCPAGdb reveals signals of pairwise
380 traits and shared signals by analyzing traits associations with LD proxy SNPs. The
381 output data will show results from Fisher's exact test with adjustment for 5% false
382 discovery rate (FDR) and also Bonferroni's, Jaccard's, Sorensen's, and Chao-
383 Sorensen similarity indexes.

384 **MR analysis**

385 We conducted a MR analysis with plasma proteins as the exposure variable and PC as
386 the outcome variable. We utilized the R package "TwoSampleMR" in R software
387 (4.3.3) for the MR analysis. When only one SNP was available for a particular

388 protein, we applied the Wald ratio test. Inverse-variance weighted (IVW) was used as
389 the main analysis method for two or more SNPs available. Considering multiple
390 testing, we employed the 5% False Discovery Rate (FDR) method for P-value
391 correction. P<0.05 was considered statistically significant. MR-Egger and weighted
392 median methods were used as supplementary analysis methods. Cochran's Q statistic
393 test using the MR-Egger method was used to determine the heterogeneity between the
394 genetic variants. We also performed MR-Egger regression intercept to detect and
395 adjust the directional horizontal pleiotropy(Hemani, Bowden, & Smith, 2018), P<0.05
396 was considered as the presence of directional pleiotropy and thus removed from the
397 further analyses.

398 **Colocalization analysis**

399 The "coloc" package was used to perform Bayesian colocalization analysis to
400 investigate if the associations between plasma proteins and PCa were driven by
401 linkage disequilibrium (LD) (Giambartolomei et al., 2014). For proteins with positive
402 MR results, the Bayesian method assessed the support for the following five exclusive
403 hypotheses: 1) no association with either trait; 2) association with trait 1 only; 3)
404 association with trait 2 only; 4) both traits are associated, but distinct causal variants
405 were for two traits; and 5) both traits are associated, and the same shares causal
406 variant for both traits(Foley et al., 2021). The posterior probability is provided for
407 each hypothesis (H0, H1, H2, H3, and H4). In this analysis, we set prior probabilities
408 of the SNP being associated with trait 1 only (p1) at 1×10^{-4}; the probability of the
409 SNP being associated with trait 2 only (p2) at 1×10^{-4}; and the probability of the SNP

410 being associated with both traits (p12) at 1×10^{-5}. Two signals were considered to
411 have strong evidence of colocalization if the posterior probability for shared causal
412 variants (PH4) was ≥0.8. The analysis was performed in R software (4.3.3).

413 **Biological pathway analysis**

414 The GENE2FUNC tool in FUMA(Watanabe, Taskesen, van Bochoven, & Posthuma,
415 2017) web application programming interface version 1.5.2 were used to investigate
416 functional annotation and enrichment analysis of the genes coding for the 193 unique
417 proteins identified by the PW-MR approach. This analysis involved calculating the
418 log2 fold-change expression for each gene across 54 tissue types from the GTEx
419 (Genotype-Tissue Expression) database. We conducted gene enrichment analysis to
420 identify overrepresented biological processes using the Gene Ontology (GO)
421 database, which helped determine the biological processes most relevant to the genes
422 identified. To investigate the involvement of the identified genes in functional and
423 signaling pathways, we used the KEGG (Kyoto Encyclopedia of Genes and Genomes)
424 pathway database. Enrichment results were considered significant if they passed 5%
425 FDR P-value threshold. Additionally, only enrichments involving at least two
426 overlapping genes with the gene sets were considered to ensure robustness and
427 biological relevance.

428 **Druggability evaluation**

429 The analysis of drug targets for the significant proteins identified in the MR Analysis
430 was conducted using data from OpenTargets(Ochoa et al., 2023) (v.22.11), which is
431 publicly accessible. We selected all drugs for which there was evidence for an

432 association with the protein of interest.

Data availability

The GWAS summary statistics of blood pQTLs from deCODE can be found at https://www.decode.com/summarydata/, and those of the UKB-PPP can be found at https://www.synapse.org/#!Synapse:syn51365303. Summary statistics of PCa from the PRACTICAL consortium can be obtained from OpenGWAS (https://gwas.mrcieu.ac.uk/), and those of the FinnGen study can be obtained from https://r10.finngen.fi/. The OpenTargets data were downloaded directly from the OpenTargets website (https://platform.opentargets.org/downloads/data).

Acknowledgements

The authors would like to thank all the participants and investigators of the studies (PRACTICAL, FinnGen, deCODE, UKB-PPP) for providing the invaluable data used in this research. Their commitment and effort have been essential for the success of this study. Furthermore, special thanks to our colleagues and collaborators for their insightful discussions and feedback throughout the research process. This research was funded by Beijing Municipal Natural Science Foundation (grant No. JQ24059, No. L234038), and National Natural Science Foundation of China (grant No. 82274015).

References

Avgeris, M., Mavridis, K., & Scorilas, A. (2012). Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. *Biol Chem, 393*(5), 301-317. doi:10.1515/hsz-2011-0260

Aye, Y., Li, M., Long, M. J. C., & Weiss, R. S. (2015). Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. *Oncogene, 34*(16), 2011-2021. doi:10.1038/onc.2014.155

Bergström, S. H., Järemo, H., Nilsson, M., Adamo, H. H., & Bergh, A. (2018). Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness. *Prostate, 78*(4), 257-265. doi:10.1002/pros.23466

Byrne, K. S., Appleby, P. N., Key, T. J., Holmes, M. V., Fensom, G. K., Agudo, A., . . . Consortium, P. (2019). The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. *Annals of Oncology, 30*(6), 983-989. doi:10.1093/annonc/mdz121

Cao, Y., Nimptsch, K., Shui, I. M., Platz, E. A., Wu, K., Pollak, M. N., . . . Giovannucci, E. L. (2015). Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. *International Journal of Cancer, 136*(10), 2418-2426. doi:10.1002/ijc.29295

Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., . . . Zietman, A. L. (2013). Early Detection of Prostate Cancer: AUA Guideline. *Journal of Urology, 190*(2), 419-426. doi:10.1016/j.juro.2013.04.119

Chen, H. Y., Lin, L. T., Wang, M. L., Laurent, B., Hsu, C. H., Pan, C. M., . . . Chiou, S. H. (2017). Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3. *Scientific Reports, 7*, 14. doi:10.1038/s41598-017-09504-7

Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E.,

Brennan, P., . . . Tsilidis, K. K. (2020). Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer, 146*(10), 2680-2693. doi:10.1002/ijc.32576

Cuchel, M., & Rader, D. J. (2006). Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? *Circulation, 113*(21), 2548-2555. doi:10.1161/circulationaha.104.475715

Cui, C., Chatterjee, B., Lozito, T. P., Zhang, Z., Francis, R. J., Yagi, H., . . . Lo, C. W. (2013). Wdpcp, a PCP Protein Required for Ciliogenesis, Regulates Directional Cell Migration and Cell Polarity by Direct Modulation of the Actin Cytoskeleton. *Plos Biology, 11*(11), 17. doi:10.1371/journal.pbio.1001720

Davies, N. M., Holmes, M. V., & Smith, G. D. (2018). Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *Bmj-British Medical Journal, 362*, 11. doi:10.1136/bmj.k601

De Mezer, M., Rogalinski, J., Przewozny, S., Chojnicki, M., Niepolski, L., Sobieska, M., & Przystanska, A. (2023). SERPINA3: Stimulator or Inhibitor of Pathological Changes. *Biomedicines, 11*(1), 15. doi:10.3390/biomedicines11010156

Deichaite, I., Sears, T. J., Sutton, L., Rebibo, D., Morgan, K., Nelson, T., . . . Carter, H. (2022). Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer. *Journal of Translational Medicine, 20*(1), 16. doi:10.1186/s12967-022-03731-x

Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012). Visceral obesity, metabolic syndrome, insulin resistance and cancer. *Proc Nutr Soc, 71*(1), 181-189. doi:10.1017/s002966511100320x

Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., . . . de Koning, H. (2009). Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. *Jnci-Journal of the National Cancer Institute, 101*(6), 374-383. doi:10.1093/jnci/djp001

Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I., Styrmisdottir, E. L., . . . Stefansson, K. (2021). Large-scale integration of the

plasma proteome with genetics and disease. *Nature Genetics, 53*(12), 1712-+. doi:10.1038/s41588-021-00978-w

Ferlay J, E. M., Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F . (2024). Global Cancer Observatory: Cancer Today. Retrieved from https://gco.iarc.who.int/today

Foley, C. N., Staley, J. R., Breen, P. G., Sun, B. B., Kirk, P. D. W., Burgess, S., & Howson, J. M. M. (2021). A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nature Communications, 12*(1), 18. doi:10.1038/s41467-020-20885-8

Foskolou, I. P., Jorgensen, C., Leszczynska, K. B., Olcina, M. M., Tarhonskaya, H., Haisma, B., . . . Hammond, E. M. (2017). Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication. *Molecular Cell, 66*(2), 206-+. doi:10.1016/j.molcel.2017.03.005

Frayling, T. M., Colhoun, H., & Florez, J. C. (2008). A genetic link between type 2 diabetes and prostate cancer - Commentary. *Diabetologia, 51*(10), 1757-1760. doi:10.1007/s00125-008-1114-9

Garde, S. V., Basrur, V. S., Li, L., Finkelman, M. A., Krishan, A., Wellham, L., . . . Tang, D. G. (1999). Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. *Prostate, 38*(2), 118-125. doi:10.1002/(sici)1097-0045(19990201)38:2<118::Aid-pros5>3.0.Co;2-g

Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *Plos Genetics, 10*(5), 15. doi:10.1371/journal.pgen.1004383

Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., . . . Reiter, R. E. (2000). Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. *Oncogene, 19*(10), 1288-1296. doi:10.1038/sj.onc.1203426

Hadaschik, B. A., Jackson, J., Fazli, L., Zoubeidi, A., Burt, H. M., Gleave, M. E., &

So, A. I. (2008). Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. *Bju International, 102*(5), 610-616. doi:10.1111/j.1464-410X.2008.07669.x

Haiman, C. A., Stram, D. O., Vickers, A. J., Wilkens, L. R., Braun, K., Valtonen-André, C., . . . Lilja, H. (2013). Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. *Jnci-Journal of the National Cancer Institute, 105*(3), 237-243. doi:10.1093/jnci/djs486

Hemani, G., Bowden, J., & Smith, G. D. (2018). Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Human Molecular Genetics, 27*(R2), R195-R208. doi:10.1093/hmg/ddy163

Hobbs, B. D., de Jong, K., Lamontagne, M., Bossé, Y., Shrine, N., Artigas, M. S., . . . Int, C. G. C. (2017). Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. *Nature Genetics, 49*(3), 426-432. doi:10.1038/ng.3752

Hockla, A., Miller, E., Salameh, M. A., Copland, J. A., Radisky, D. C., & Radisky, E. S. (2012). PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer. *Molecular Cancer Research, 10*(12), 1555-1566. doi:10.1158/1541-7786.Mcr-12-0314

Humphries, A. C., & Mlodzik, M. (2018). From instruction to output: Wnt/PCP signaling in development and cancer. *Current Opinion in Cell Biology, 51*, 110-116. doi:10.1016/j.ceb.2017.12.005

Iqbal, W., Demidova, E. V., Serrao, S., ValizadehAslani, T., Rosen, G., & Arora, S. (2021). RRM2B Is Frequently Amplified Across Multiple Tumor Types: Implications for DNA Repair, Cellular Survival, and Cancer Therapy. *Frontiers in Genetics, 12*, 13. doi:10.3389/fgene.2021.628758

Ito, K., Yamamoto, T., Hayashi, Y., Sato, S., Nakayama, J., Urabe, F., . . . Yamamoto, Y. (2023). Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer. *Molecular Oncology, 17*(10), 2147-2167. doi:10.1002/1878-0261.13484

James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., . . . Xie, L.-P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. *Lancet (London, England), 403*(10437), 1683-1722. doi:10.1016/s0140-6736(24)00651-2

Jansen, B., & Zangemeister-Wittke, U. (2002). Antisense therapy for cancer - the time of truth. *Lancet Oncology, 3*(11), 672-683. doi:10.1016/s1470-2045(02)00903-8

Jiang, G. Z., Cao, F. Y., Ren, G. P., Gao, D. L., Bhakta, V., Zhang, Y. H., . . . Wang, Y. H. (2010). PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. *Gut, 59*(11), 1535-1544. doi:10.1136/gut.2009.200105

Kamada, M., So, A., Muramaki, M., Rocchi, P., Beraldi, E., & Gleave, M. (2007). Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. *Molecular Cancer Therapeutics, 6*(1), 299-308. doi:10.1158/1535-7163.Mct-06-0417

Kaufman, K. D. (1996). Androgen metabolism as it affects hair growth in androgenetic alopecia. *Dermatol Clin, 14*(4), 697-711. doi:10.1016/s0733-8635(05)70396-x

Lawrence, M. G., Lai, J., & Clements, J. A. (2010). Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. *Endocr Rev, 31*(4), 407-446. doi:10.1210/er.2009-0034

Li, E. M., Liu, L. H., Li, F. T., Luo, L. M., Zhao, S. K., Wang, J. M., . . . Zhao, Z. G. (2017). PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc. *Prostate, 77*(16), 1563-1572. doi:10.1002/pros.23432

Liang, Z., Xie, B., Li, J., Wang, X., Wang, S., Meng, S., . . . Xie, L. (2016). Hypertension and risk of prostate cancer: a systematic review and meta-analysis. *Scientific Reports, 6*, 31358. doi:10.1038/srep31358

Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. *Nat Rev Cancer, 8*(4), 268-278.

599 doi:10.1038/nrc2351
600 Machiela, M. J., Lindström, S., Allen, N. E., Haiman, C. A., Albanes, D., Barricarte,
601 A., . . . Kraft, P. (2012). Association of Type 2 Diabetes Susceptibility Variants
602 With Advanced Prostate Cancer Risk in the Breast and Prostate Cancer Cohort
603 Consortium. *American Journal of Epidemiology, 176*(12), 1121-1129.
604 doi:10.1093/aje/kws191
605 Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related
606 inflammation. *Nature, 454*(7203), 436-444. doi:10.1038/nature07205
607 Martuszewska, D., Ljungberg, B., Johansson, M., Landberg, G., Oslakovic, C.,
608 Dahlbäck, B., & Hafizi, S. (2009). Tensin3 Is a Negative Regulator of Cell
609 Migration and All Four Tensin Family Members Are Downregulated in
610 Human Kidney Cancer. *Plos One, 4*(2), 13. doi:10.1371/journal.pone.0004350
611 Mavridis, K., Avgeris, M., & Scorilas, A. (2014). Targeting kallikrein-related
612 peptidases in prostate cancer. *Expert Opin Ther Targets, 18*(4), 365-383.
613 doi:10.1517/14728222.2014.880693
614 Moyad, M. A. (2015). Preventing aggressive prostate cancer with proven
615 cardiovascular disease preventive methods. *Asian J Androl, 17*(6), 874-877;
616 discussion 876. doi:10.4103/1008-682x.156854
617 Nakajima, T., Fujino, S., Nakanishi, G., Kim, Y. S., & Jetten, A. M. (2004). TIP27: a
618 novel repressor of the nuclear orphan receptor TAK1/TR4. *Nucleic Acids*
619 *Research, 32*(14), 4194-4204. doi:10.1093/nar/gkh741
620 Nam, R. K., Reeves, J. R., Toi, A., Dulude, H., Trachtenberg, J., Emami, M., . . .
621 Narod, S. A. (2006). A novel serum marker, total prostate secretory protein of
622 94 amino acids, improves prostate cancer detection and helps identify high
623 grade cancers at diagnosis. *Journal of Urology, 175*(4), 1291-1297.
624 doi:10.1016/s0022-5347(05)00695-6
625 Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., . . .
626 McDonagh, E. (2023). The next-generation Open Targets Platform:
627 reimagined, redesigned, rebuilt. *Nucleic Acids Research, 51*(D1), D1353-
628 D1359. doi:10.1093/nar/gkac1046

Oesterling, J. E. (1991). PROSTATE SPECIFIC ANTIGEN - A CRITICAL-ASSESSMENT OF THE MOST USEFUL TUMOR-MARKER FOR ADENOCARCINOMA OF THE PROSTATE. *Journal of Urology, 145*(5), 907-923. doi:10.1016/s0022-5347(17)38491-4

Okumura, H., Natsugoe, S., Matsumoto, M., Mataki, Y., Takatori, H., Ishigami, S., . . . Aikou, T. (2005). The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. *British Journal of Cancer, 92*(2), 284-289. doi:10.1038/sj.bjc.6602322

Okuno, M., Adachi, S., Kozawa, O., Shimizu, M., & Yasuda, I. (2016). The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. *International Journal of Molecular Sciences, 17*(1), 7. doi:10.3390/ijms17010137

Ossoli, A., Wolska, A., Remaley, A. T., & Gomaraschi, M. (2022). High-density lipoproteins: A promising tool against cancer. *Biochim Biophys Acta Mol Cell Biol Lipids, 1867*(1), 159068. doi:10.1016/j.bbalip.2021.159068

Perez-Cornago, A., Dunneram, Y., Watts, E. L., Key, T. J., & Travis, R. C. (2022). Adiposity and risk of prostate cancer death: a prospective analysis in UK Biobank and meta-analysis of published studies. *Bmc Medicine, 20*(1), 13. doi:10.1186/s12916-022-02336-x

Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., . . . Zaniboni, A. (2021). Association of Obesity With Survival Outcomes in Patients With Cancer A Systematic Review and Meta-analysis. *Jama Network Open, 4*(3), 30. doi:10.1001/jamanetworkopen.2021.3520

Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M. A., . . . Langenberg, C. (2021). Mapping the proteo-genomic convergence of human diseases. *Science, 374*(6569), 839-+. doi:10.1126/science.abj1541

Reeves, J. R., Dulude, H., Panchal, C., Daigneault, L., & Ramnani, D. M. (2006). Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. *Clinical Cancer Research, 12*(20), 6018-6022. doi:10.1158/1078-0432.Ccr-06-0625

Rohatgi, A., Westerterp, M., von Eckardstein, A., Remaley, A., & Rye, K. A. (2021). HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. *Circulation, 143*(23), 2293-2309. doi:10.1161/circulationaha.120.044221

Rosario, S. R., Jacobi, J. J., Long, M. D., Affronti, H. C., Rowsam, A. M., & Smiraglia, D. J. (2023). JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy. *Molecular Cancer Research, 21*(1), 24-35. doi:10.1158/1541-7786.Mcr-22-0316

Ruscica, M., Botta, M., Ferri, N., Giorgio, E., Macchi, C., Franceschini, G., . . . Gomaraschi, M. (2018). High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation. *Scientific Reports, 8*(1), 2236. doi:10.1038/s41598-018-19568-8

Saxena, R., Voight, B. F., Zeggini, E., Scott, L. J., & Genetics, I. C. D. (2008). Meta-analysis of genome-wide association data and large-scale replication identifies several additional susceptibility loci for type 2 diabetes. *Diabetes, 57*, A41-A41. Retrieved from <Go to ISI>://WOS:000256612000133

Schumacher, F. R., Al Olama, A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders, E. J., . . . Elucidating Loci Involved, P. (2018). Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics, 51*(2), 363-363. doi:10.1038/s41588-018-0330-6

Seretis, A., Cividini, S., Markozannes, G., Tseretopoulou, X., Lopez, D. S., Ntzani, E. E., & Tsilidis, K. K. (2019). Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. *Scientific Reports, 9*(1), 8565. doi:10.1038/s41598-019-45014-4

Sheng, B. W., Qi, C. C., Liu, B., Lin, Y., Fu, T., & Zeng, Q. D. (2017). Increased HSP27 correlates with malignant biological behavior of non-small cell lung cancer and predicts patient's survival. *Scientific Reports, 7*, 12. doi:10.1038/s41598-017-13956-2

Shi, D. B., Ma, R. R., Zhang, H., Hou, F., Guo, X. Y., & Gao, P. (2019). GAGE7B promotes tumor metastasis and growth via activating the

p38/pMAPKAPK2/pHSP27 pathway in gastric cancer. *Journal of Experimental & Clinical Cancer Research, 38*, 12. doi:10.1186/s13046-019-1125-z

Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., . . . Zoubeidi, A. (2013). Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer. *Cancer Research, 73*(10), 3109-3119. doi:10.1158/0008-5472.Can-12-3979

Stikbakke, E., Schirmer, H., Knutsen, T., Støyten, M., Wilsgaard, T., Giovannucci, E. L., . . . Thune, I. (2022). Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study. *Cancer Med, 11*(4), 1005-1015. doi:10.1002/cam4.4523

Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y. H., Richardson, T. G., . . . Whelan, C. D. (2023). Plasma proteomic associations with genetics and health in the UK Biobank. *Nature, 622*(7982), 329-338. doi:10.1038/s41586-023-06592-6

Sung, Y., Park, S., Park, S. J., Jeong, J., Choi, M., Lee, J., . . . Kim, M. O. (2018). Jazf1 promotes prostate cancer progression by activating JNK/Slug. *Oncotarget, 9*(1), 755-765. doi:10.18632/oncotarget.23146

Teng, K. Y., Mansour, A. G., Zhu, Z., Li, Z. Y., Tian, L., Ma, S. B., . . . Yu, J. H. (2022). Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. *Gastroenterology, 162*(4), 1319-1333. doi:10.1053/j.gastro.2021.12.281

Thomas, G., Jacobs, K. B., Yeager, M., Kraft, P., Wacholder, S., Orr, N., . . . Chanock, S. J. (2008). Multiple loci identified in a genome-wide association study of prostate cancer. *Nature Genetics, 40*(3), 310-315. doi:10.1038/ng.91

Tong, Y., Guo, Y. J., Zhang, Q., Bi, H. X., Kai, K., & Zhou, R. Y. (2022). Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells. *Asian J Androl, 24*(5), 513-520. doi:10.4103/aja2021114

Vasiljevic, N., Ahmad, A. S., Beesley, C., Thorat, M. A., Fisher, G., Berney, D. M., . . . Lorincz, A. T. (2013). Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. *Prostate Cancer and Prostatic Diseases, 16*(1), 35-40. doi:10.1038/pcan.2012.47

Wain, L. V., Shrine, N., Artigas, M. S., Erzurumluoglu, A. M., Noyvert, B., Bossini-Castillo, L., . . . Geisinger-Regeneron Discov, E. H. R. (2017). Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. *Nature Genetics, 49*(3), 416-425. doi:10.1038/ng.3787

Wang, L., Balmat, T. J., Antonia, A. L., Constantine, F. J., Henao, R., Burke, T. W., . . . Ko, D. C. (2020). An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility. *medRxiv : the preprint server for health sciences*. doi:10.1101/2020.12.20.20248572

Wang, X. J., & Su, H. B. (2010). Unraveling Enigma in the Z-Disk. *Circulation Research, 107*(3), 321-323. doi:10.1161/circresaha.110.225615

Watanabe, K., Taskesen, E., van Bochoven, A., & Posthuma, D. (2017). Functional mapping and annotation of genetic associations with FUMA. *Nature Communications, 8*, 11. doi:10.1038/s41467-017-01261-5

Xie, P. B., Liu, M. S., Chen, F., Wu, S. M., Shao, T., Wang, W., . . . Zhou, H. Q. (2020). Long Non-coding RNA AGAP2-AS1 Silencing Inhibits PDLIM5 Expression Impeding Prostate Cancer ProgressionviaUp-Regulation of MicroRNA-195-5p. *Frontiers in Genetics, 11*, 13. doi:10.3389/fgene.2020.01030

Xing, C. J., Ye, H., Wang, W. W., Sun, M. M., Zhang, J. Y., Zhao, Z. H., & Jiang, G. Z. (2019). Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression. *Artificial Cells Nanomedicine and Biotechnology, 47*(1), 3920-3928. doi:10.1080/21691401.2019.1671856

Xing, Z. S., Li, S. L., Liu, Z. X., Zhang, C., & Bai, Z. M. (2021). CircSERPINA3

749 regulates SERPINA3-mediated apoptosis, autophagy and aerobic glycolysis of
750 prostate cancer cells by competitively binding to MiR-653-5p and recruiting
751 BUD13. *Journal of Translational Medicine, 19*(1), 13. doi:10.1186/s12967-
752 021-03063-2
753 Zheng, J. Y., Wang, C. Y., Gao, C., Xiao, Q., Huang, C. W., Wu, M., & Li, L. Y.
754 (2021). MLL3 suppresses tumorigenesis through regulating TNS3 enhancer
755 activity. *Cell Death & Disease, 12*(4), 13. doi:10.1038/s41419-021-03647-2
756 Zhigang, Z., & Wenlv, S. (2004). Prostate stem cell antigen (PSCA) expression in
757 human prostate cancer tissues and its potential role in prostate carcinogenesis
758 and progression of prostate cancer. *World journal of surgical oncology, 2*, 13.
759 doi:10.1186/1477-7819-2-13
760 Zhou, M. Y., Li, K. K., & Luo, K. Q. (2023). Shear Stress Drives the Cleavage
761 Activation of Protease-Activated Receptor 2 by PRSS3/Mesotrypsin to
762 Promote Invasion and Metastasis of Circulating Lung Cancer Cells. *Advanced*
763 *Science, 10*(25), 21. doi:10.1002/advs.202301059
764 Zuidema, A., Atherton, P., Kreft, M., Hoekman, L., Bleijerveld, O. B., Nagaraj,
765 N., . . . Sonnenberg, A. (2022). PEAK1 Y635 phosphorylation regulates cell
766 migration through association with Tensin3 and integrins. *Journal of Cell*
767 *Biology, 221*(8), 18. doi:10.1083/jcb.202108027

Graphical abstract:





Figure 1. Manhattan plot of PCa GWAS meta-analysis. The genetic regions containing top SNPs related to PCa are depicted. The red dashed line signifies the genome-wide significance threshold of 5.0×10^{-8}.



Figure 2. The top 10 significant cross-phenotype associations with PCa at a 5% FDR. The x-axis represents the P value of the correlation. BMI, body mass index.



Figure 3. Result of PW-MR on the associations between plasma proteins and the risk of PCa. (A) Volcano plot of PCa PW-MR study using deCODE (the left side) and UKB-PPP (the right side) cohorts. Annotated proteins passed the 5% FDR IVW P-value threshold. The blue and red colors represent a negative and positive effect, respectively. (B) Venn diagram depicting proteins associated with PCa in deCODE and UKB-PPP. (C) PhenoGram of PCa PW-MR study significant associations. The blue dots and the green dots represent the deCODE and UKB-PPP specific proteins, respectively. The red dot represents both simultaneously.



Figure 4. Colocalization plot of SERPINA3 variants associated with PCa in deCODE and UKB-PPP. Variants are color-coded based on their linkage disequilibrium (LD) with the lead SNP (the variant with the lowest p-value). The lead SNP is highlighted in red. Other variants are colored from blue to yellow, indicating decreasing LD with the lead SNP.



Figure 5. Functional annotation of the genetic architecture of PCa. (A) Biological processes and (B) KEGG pathway analysis of the 193 unique proteins identified in deCODE and UKB-PPP.